Clinical Trial

VA as Maintenance Therapy Post Allo-HSCT in MDS and AML

Name: VA as Maintenance Therapy Post Allo-HSCT in MDS and AML — clinical trial record (NCT06598384)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The goal of this phase 2 trial is to test the safety and efficacy of Venetoclax combined with Azacytidine as Maintenance Therapy post Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-09-13.

Trial Details

NCT Number	NCT06598384
Lead Sponsor	Navy General Hospital, Beijing
Conditions	Acute Myeloid Leukemia
Enrollment	40 participants
Start Date	2024-09
Primary Completion	2030-09 (estimated)
Study Completion	2030-09 (estimated)
Updated on ClinicalTrials.gov	2024-10-01